Robert Bell

MemeryCrystal, Armstrong Teasdale (London)
Partner / Consultant

Robert Bell is a competition & regulatory specialist in the corporate department of Armstrong Teasdale with over 30 years’ experience advising clients on complex competition and regulatory matters involving some of the leading cases before the Competition & Markets Authority, the European Commission, and the UK Courts. He has advised clients on a range of competition law issues including merger control, cartels, competition investigations and competition litigation, representing them before competition regulators like the CMA, OFCOM, FCA and the EU Commission and national courts.


2858 Bulletin

Robert Bell The UK Competition Appeal Tribunal dismisses the appeal brought by a manufacturer of golf equipment on the liability of anticompetitive practices but permits a small reduction of the fine (Ping)


UK LANDMARK COMPETITION CASE CONDEMNS ABSOLUTE INTERNET SALE BAN AS A SERIOUS BREACH OF COMPETITION LAW* Introduction The Competition Appeal Tribunal (“CAT”) handed down its judgment on 7 September 2018 in relation to an appeal by Ping Europe Limited (“Ping”) challenging the decision of the UK (...)

Robert Bell The UK Competition Authority publishes a Guidance on changes to the jurisdictional thresholds for UK mergers control and extends the control on mergers related to sensitive sectors


GREATER NATIONAL SECURITY SCRUTINY AT THE HEART OF NEW UK MERGER CONTROL REFORMS* This week the UK Government enacted two new Orders which lower the UK merger control thresholds under the Enterprise Act 2002. The legislation extends the jurisdiction of the Competition and Markets Authority (...)

Robert Bell The UK Competition Appeal Tribunal finds an incorrect application of the legal test for dominance and quashes the Competition Authority’s record fines imposed on two pharmaceutical companies for charging excessive prices for an anti-epilepsy drug (Pfizer / Flynn)


EXCESSIVE PRICE? COMPARED TO WHAT?* On 7 June 2017, the Competition Appeal Tribunal (“CAT”) set aside parts of the Competition & Market Authority’s (“CMA”) decision in relation to the CMA’s finding that Pfizer and Flynn charged excessive and unfair prices for phenytoin sodium capsules and (...)

Paul Culliford, Robert Bell The EU Court of Justice clarifies the scope of gun jumping prohibition by excluding cooperation agreements which don’t contribute to the change in control of the target business (EY / KPMG)


EUROPEAN COURT OF JUSTICE CLARIFIES SCOPE OF GUN JUMPING PROHIBITION* Over the last year, we have noted an increased crackdown by competition agencies on so-called “gun jumping” – that is, the implementation of a merger before mandatory merger clearances are received. On 31 May 2018, the European (...)

Send a message